Michael Honigberg is a Cardiology physician. ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics need a complete publication history and a confident author match. We omit them when either check fails. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
- Cardiac Effects of Mineralocorticoid Receptor Antagonism After Preeclampsia
Sponsor: Massachusetts General Hospital
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novartis Pharmaceuticals CorporationProgram year20252 payments
- Cleerly, Inc.Program year20251 payment
- Novartis Pharmaceuticals CorporationProgram year20244 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
83.7%Statin27.8%Atorvastatin Calcium66%Rosuvastatin Calcium34%Part D≥25 patientsPCSK9 Inhibitor12.9%Repatha Sureclick54%Repatha Syringe26%Praluent Pen20%Part D<11 patients+ 6 more classes in this area
Metabolism & gastrointestinal
16.3%GLP-1 receptor agonist8.6%Wegovy67%Ozempic33%Part D<11 patientsSGLT2 inhibitor7.7%Farxiga56%Jardiance44%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
3 NIH research awards on record, funded 2023–2026 per NIH RePORTER. The latest:
- Effects of IL-1 beta inhibition on vascular inflammation in TET2 clonal hematopoiesis
Massachusetts General Hospital
FY2026$816,874R01HL173028 - Cardiac Effects of Mineralocorticoid Receptor Antagonism after Preeclampsia (CARDAMOM)
Massachusetts General Hospital
FY2026$671,741R01HL181150 - Effects of IL-1 beta inhibition on vascular inflammation in TET2 clonal hematopoiesis
Massachusetts General Hospital
FY2025$834,531R01HL173028
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Deepak Bhatt, MD
Icahn School of Medicine at Mount Sinai
Harlan Krumholz, MD
Yale School of Medicine
Martin Leon, MD
Columbia University Irving Medical Center
Scott Solomon, MD
Brigham and Women's Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”